Results from subgroup analyses of the Evaluate Renal Function with Semaglutide Once Weekly (FLOW), the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT), the Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF), and the Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction and Diabetes Mellitus (STEP-HFpEF DM) trials showed that semaglutide tended to be more effective in younger patients, those with higher BMI, higher GFR, and lower HbA1c levels 22,23,24
SunXBWuXJChenXYGuoRKouYXLiXJet al
However, its important to consult with a healthcare provider to fully understand the potential risks and benefits, especially if other underlying conditions, such as diabetes or autoimmune disorders, are present
As the evidence base solidifies, the future of OA care lies in personalization, tailoring nutritional plans based on genetics, gut microbiota, and individual metabolic profiles
